← All trials
NCT05796401
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 15, 2023
- Primary completion
- Jul 15, 2026
- Completion date
- Jun 15, 2028
- First posted
- Apr 3, 2023
- Last posted
- Apr 27, 2023
- Enrollment
- 500
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Centre Hospitalier St AnneLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.